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Abstract
AIM
To assess clinical outcomes for submucosal (T1b) oeso-
phageal adenocarcinoma (OAC) patients managed with 
either surgery or endoscopic eradication therapy.
METHODS
Patients found to have T1b OAC following endoscopic 
resection between January 2008 to February 2016 at 
University College London Hospital were retrospectively 
analysed. Patients were split into low-risk and high-risk 
groups according to established histopathological criteria 
and were then further categorised according to whether 
they underwent surgical resection or conservative man-
agement. Study outcomes include the presence of lymph-
node metastases, disease-specific mortality and overall 
survival. 
RESULTS
A total of 60 patients were included; 22 patients were 
surgically managed (1 low-risk and 21 high-risk patients) 
whilst 38 patients were treated conservatively (12 low-risk 
and 26 high risk). Overall, lymph node metastases (LNM) 
were detected in 10 patients (17%); six of these patients 
had undergone conservative management and LNM were 
detected at a median of 4 mo after endoscopic mucosal 
resection (EMR). All LNM occurred in patients with high-
risk lesions and this represented 21% of the total high-risk 
lesions. Importantly, there was no statistically significant 
difference in tumor-related deaths between those treated 
surgically or conservatively (P = 0.636) and disease-spe-
cific survival time was also comparable between the two 
treatment strategies (P = 0.376).
CONCLUSION
T1b tumours without histopathological high-risk markers 
of LNM can be treated endoscopically with good out-
comes. In selected patients, endoscopic therapy may be 
appropriate for high-risk lesions.
Key words: Oesophageal adenocarcinoma; Submucosal 
invasion; T1b; Lymph node metastasis; Risk prediction; 
Endoscopy
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Our retrospective cohort data supports pre-
viously published work demonstrating that endoscopic 
therapy is a safe and effective option for T1b oesophageal 
adenocarcinoma without markers of high-risk for lymph-
node metastasis. Furthermore, our work suggests that 
endoscopic therapy is a viable alternative to surgery in 
selected patients with high-risk lesions (particularly those 
with poor performance status) and highlights the need for 
further work exploring whether endoscopic therapy could 
be a viable option for all submucosal lesions.
Graham D, Sever N, Magee C, Waddingham W, Banks M, Sweis 
R, Al-Yousuf H, Mitchison M, Alzoubaidi D, Rodriguez-Justo 
M, Lovat L, Novelli M, Jansen M, Haidry R. Risk of lymph node 
metastases in patients with T1b oesophageal adenocarcinoma: 
A retrospective single centre experience. World J Gastroenterol 
2018; 24(41): 0000-0000  Available from: URL: http://www.
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INTRODUCTION
Endoscopic eradication therapy (EET) for the treatment 
of early neoplasia arising in Barrett’s oesophagus (BE) 
is widely established to avoid progression to advanced 
oesophageal adenocarcinoma (OAC). This approach 
is safe and highly effective with data demonstrating 
minimal risk to patients with durable long- term disease 
free survival. Prospective data from several high-volume 
studies demonstrate our ability to successfully treat 
BE-related neoplasia has markedly improved over the 
past 10 years. Following EET the complete resolution 
of dysplasia is above 90% and the complete resolution 
of intestinal metaplasia is above 80% at one year[1-4]. 
Endoscopic resection and subsequent field ablation with 
radiofrequency ablation (RFA) is the established standard 
of care for the majority of patients with BE-related 
neoplasia confined to the mucosa (dysplasia and T1a 
OAC)[5-7].
Compared to T1a OAC, the decision making and 
optimal management strategy for patients with BE neo-
plasia where lesions have submucosal invasion (T1b) is 
less well-defined (Figure 1). Historically, these lesions 
are thought to be associated with a significantly higher 
risk of subsequent loco-regional lymph node metastases 
(LNM) compared to T1a OAC and therefore surgery with 
oesophagectomy and nodal clearance is offered[8-13]. How-
ever, emerging data suggest that lesions confined to the 
uppermost layer of the submucosa (T1bSm1) with low-
risk histological features (complete resection, lack of poor 
tumour differentiation and no lymphovascular invasion) 
may have a rate of LNM comparable to the 30-d mor-
tality of surgery with oesophagectomy, leaving aside 
the surgery related morbidity and reduced quality of life 
that those who undergo this operation endure[8,10,14-19]. 
Given these figures EET with endoscopic follow-up may 
therefore be appropriate treatment for these patients 
with low-risk T1b OAC. Although solid clinical data are 
lacking, several societies now advocate this conservative 
management approach for low-risk T1bSm1 OAC pa-
tients[5-7]. Surgical resection remains the gold standard 
treatment for patients who have T1bSm1 lesions with 
high-risk histological features or in whom the lesion ex-
tends beyond the uppermost layer of the submucosa 
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(Sm2/3) in view of the significantly higher rate of sub-
sequent LNM. Emerging data suggest that in selected 
high risk T1b patients, most notably those deemed unfit 
to undergo surgical management, conservative follow-
up may be a valid alternative although again larger 
prospective high-quality studies are lacking[16,18,19].
The aim of this single-centre retrospective cohort 
study was to assess the risk of LNM in consecutive pa-
tients found to have T1b OAC following endoscopic re-




Consecutive patients who were found to have a T1b OAC 
on endoscopic resection specimen at University College 
London Hospital from January 2008 to February 2016 
were retrospectively analysed for this study. Patients 
were included if they had OAC arising within BE with 
submucosal invasion on endoscopic resection specimen. 
Exclusion criteria were the presence of LNM at baseline 
staging prior to endoscopic mucosal resection (EMR) or 
distant metastases on diagnostic staging with adjunct 
imaging [endoscopic ultrasonography (EUS), computed 
tomography (CT), positron emission tomography (PET)-
CT], follow-up time shorter than 24 mo, and insufficient 
or incomplete follow-up data. For example if patients 
with a high risk visible lesion (large polypoid lesion or 
ulcerated lesion) would undergo EUS, PET-CT and CT 
scan. If any were found to have LNM then they would 
not undergo EMR. Patients were not excluded if they had 
received previous EET for dysplasia within BE [including 
photodynamic therapy, argon plasma coagulation (APC), 
radiofrequency ablation (RFA) or endoscopic resection] 
prior to the T1b OAC diagnosis. 
Endoscopic resection
All endoscopic resections were performed by endoscopic 
mucosal resection (EMR) with multiband mucosectomy 
technique (Duette, Cook Endoscopy or Captivator, Boston 
Scientific).
Histopathology
Resected specimens were reviewed by two expert gas-
trointestinal pathologists, who reported on each of the 
following tumour characteristics: depth of submucosal 
invasion[15], tumour differentiation, lymphovascular inva-
sion, and presence of tumour cells within or less than 
1000 μm from the vertical resection margin. If the initial 
histopathology report was incomplete or made by a non-
expert gastrointestinal histopathologist, the slides were 
reviewed by a third expert gastrointestinal pathologist for 
the purpose of this study before the patient was included 
or excluded. If a tumour characteristic was inconclusive 
despite re-evaluation it was reported as such and con-
sidered a high-risk feature in further assessment.
Treatment after initial EMR
All patients were discussed at a multidisciplinary meeting 
(MDM) attended by gastroenterologists, upper gastro-
intestinal surgeons, oncologists, radiologists and histo-
pathologists. Further treatment plans were formulated 
based on tumour histopathological characteristics found 
on EMR specimen, diagnostic staging (EUS and/or CT 
and/or PET-CT), and a patient’s surgical fitness, medical 
history and preferences. Patients, with OAC T1b, who 
were eligible for surgery underwent oesophagectomy 
with lymphadenectomy. After histopathologic review of 
surgically resected specimen, some patients received 
chemoradiotherapy (CRT) if they were upstaged or if 
there was evidence of LNM on pathology. Conservative 
treatment included additional endoscopic eradication 
therapy with field ablation (RFA, APC) or further EMR in 
an attempt to eradicate residual flat dysplasia and meta-
plastic BE mucosa.
Follow-up
After the planned EET was concluded and successful 
eradication of disease histologically confirmed, patients 
received follow up by one or more of the following mo-
dalities: upper GI endoscopy with biopsies, EUS, CT and/
or PET-CT in order to exclude local recurrence, LNM or 
distant metastases. Patients who had achieved complete 
eradication of BE-related neoplasia were followed-up 
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Figure 1  Superficially invasive T1b oesophageal adenocarcinoma. A: Low power overview of the lesion. A moderately differentiated oesophageal adenocarcinoma 
(OAC) is located at the squamocolumnar junction. This is a piecemeal excision of this lesion. The deep margin is clear (R0). There was no lymphovascular invasion or 
poor differentiation. Boxed area shown in B. B: High power of the invasive front showing a tumour gland just penetrating the original muscularis mucosae (asterisk). 
a
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Clinical outcomes 
The following primary outcomes have been assessed 
in this study: (1) Incidence of LNM and/or distant meta-
stases after index EMR; (2) Survival of patients (time in 
months from the initial EMR until death or the end of the 
study); and (3) Surgical mortality, OAC-related and non-
OAC-related deaths.
Statistical analysis
Statistical analysis was performed using SPSS software 
(IBM, ver. 23). Parameters included Kaplan-Meier esti-
mator compared with log-rank (Mantel-Cox) test for 
survival and average or median with range and/or inter-
quartile range [IQR = first quartile (Q1) - third quartile 
(Q3)] for continuous variables compared with long-rank 
(Mantel-Cox) test or Mann-Whitney-Wilcoxon test in case 
of non-normal distribution. Categorical variables were 
expressed as percentages and compared with Pearson 
Chi-Square or Fischer’s exact test.
RESULTS
Patient demographics
During the study period 68 potential patients were iden-
tified. Eight patients were excluded as they did not meet 
the inclusion criteria: 6 had short follow up time (< 24 
mo from EMR), one had insufficient follow up data and 
one patient was upstaged after histopathologic review (T2 
- muscularis propria invasion). A total of 60 patients were 
included in the study, 85% were male and the mean 
age at the time of the initial EMR was 70 years (range 
66-75). The mean length of BE circumference (C) at 
baseline was 5 cm (range 0-13) and maximum (M) 7 cm 
(range 1-15). Sixty one percent of patients were under 
endoscopic surveillance for BE when the T1b OAC lesion 
was detected. The median period of time within the BE 
surveillance programme was 6 years (IQR 3-9) (Table 1). 
Based on the aforementioned histopathological criteria, 
13/60 (22%) patients had LR tumours and 47/60 (78%) 
had HR tumours (Table 2).
Treatment after EMR
After initial EMR 22/60 (37%) patients underwent oeso-
phagectomy; one patient from the LR group and 21 
patients from the HR group. There were 38/60 (63%) 
patients treated conservatively; 12 patients from the LR 
group and 26 patients from the HR group (Figure 2).
Surgical treatment
There was no surgical mortality observed in our cohort. 
Most patients had an Ivor-Lewis procedure (18/22), 2 
patients underwent oesophagogastrectomy, one patient 
had a three stage oesophagectomy, and one patient had 
a transhiatal resection. Surgery was performed at an 
average of 3 mo (range 1-10) after the EMR. Residual 
OAC after EMR was found in 14/22 (64%) surgically 
resected specimens and staged as T1a (4 patients), 
T1b (7 patients), T2 (2 patients) and T3 (1 patient). All 
endoscopically by 3, 6, 9, 12, 18 and 24 mo intervals and 
then annually thereafter. 
Data collection
Data were collected from March 2000 until July 2017 or 
until death of the patient. Information sources included 
medical history, endoscopic procedures, histopathology 
reports, imaging studies, outpatient clinic reports, MDM 
records and correspondence with referring hospitals and 
general practitioners.
Patient groups
For the purpose of our study, patients were divided into 2 
tumour risk groups based on the histopathological assess-
ment of the initial EMR specimens: low-risk (LR group) 
and high-risk (HR group). The characteristics of the OAC 
lesions within the low-risk (LR group) were superficial 
submucosal invasion (Sm1, < 500 μm), well or moderate 
tumour differentiation (G1-2), complete resection (R0), 
and absence of lymphovascular invasion (LVI-). These 
features have previously been demonstrated to be inde-
pendent risk factors carrying a favourable prognosis 
due to a low propensity for metastases[11,13,20]. British, 
European and American BE neoplasia guidelines employ 
similar criteria if a conservative approach over surgery 
is considered, especially in patients who are poor candi-
dates for [5-7].
The OAC lesions within the high-risk (HR group) con-
sisted of tumours exhibiting one or more of the following 
features: deep submucosal invasion (Sm2/3, > 500 
μm); poor tumour differentiation (G3); lymphovascular 
invasion (LVI+); or incomplete resection (R1). Tumours 
were also considered high-risk if any histopathologic 
feature was indefinite (X), despite re-evaluation by an 
expert histopathologist.
When combining risk groups with treatment moda-
lities, patients were further divided into LR - conservative 
treatment (LR-conservative), LR - surgical treatment (LR-
surgery), HR - conservative treatment (HR-conservative), 
and HR - surgical treatment (HR-surgery). A study flow-
chart is depicted in Figure 2.
Patients
   Total, n 60 (00%)
   Average age at EMR (IQR) 70 (66-75)
   Gender
      Male 5 (85%)
      Female 9 (5%)
Barrett's oesophagus
   Circumference (range) 5 (0-3)
   Maximum (range) 7 (-5)
   In surveillance program
      Yes, median years (IQR) 36 (6%), 6 (3-9)
      No, new finding 9 (32%)
      Data N/A 5 (7%)
Table 1  Patient demographics
EMR: Endoscopic mucosal resection; IQR: Interquartile range; N/A: Not 
available.
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these patients had an incompletely resected (R1) tumour 
on initial EMR. In 7/22 (32%) patients who underwent 
surgery, there was no evidence of residual tumour in 
the surgical resection specimen despite being classified 
as R1 on initial EMR. One patient with R0 EMR also had 
no residual cancer in surgical specimen confirming the 
initial histopathological assessment. One patient went 
on to have CRT following surgery. This patient had an R1 
surgical resection of a T2 tumour with cancer cells pre-
sent at less than 1 mm from the oesophageal resection 
margin. Residual dysplasia in the surgical margin was 
reported in 4/22 (18%) patients. Case specific details are 
summarized in Table 3.
A median of 20 lymph nodes (IQR 15-24, range 
11-55) were retrieved per surgical patient. LNM were 
found in 4/22 (18%) of the surgical resection specimens. 
These four patients all had G3 tumours, three of which 
showed lymphovascular invasion and one where this 
could not be determined (LVIX). Two of these four cases 
were Sm2/3 and the other two were SmX. None of 
the patients with an Sm1 tumour, regardless of other 
histological markers of risk, was found to have LNM. In 
addition, none of the patients who did not have lympho-
vascular invasion on the EMR specimen developed LNM. 
When stratified by histological high-risk feature, 9/22 
Outcomes by risk category Patients included
n  = 60
Low risk


















Outcomes by treatment mordality
Conservative
n  = 38
(12LR, 26HR)
Surgery









n  = 47
HR-surgery
n  = 21
HR-conservative
n  = 26
LR-sugery
n  = 1
LR-conservative
n  = 12
Figure 2  Flowchart depicting patient subgroups and outcomes. Overall median follow-up 41 mo (IQR 26-53). OAC: Oesophageal adenocarcinoma; LR: Low-risk 
tumour; HR: High-risk tumour; IQR: Interquartile range.
Tumour location
   Oesophagus 55 (92)
   Cardia (Siewert  lesions) 5 (8)
Tumour histopathology
   Differentiation
      Well (G) 2 (3)
      Moderate (G2) 28 (47)
      Poor (G3) 29 (49)
      X (GX)  ()
   Depth of submucosal invasion
      Sm (< 500 μm) 25 (42)
      Sm2/3 (> 500 μm) 25 (42)
      X 0 (6)
   Lymphovascular invasion
      Negative (LVI-) 40 (67)
      Positive (LVI+) 4 (23)
      X (LVX) 6 (0)
   Resection (vertical margin)
      Complete (R0) 7 (28)
      Incomplete (R) 43 (84)
Tumour risk group
   Low-risk (LR) 3 (22)
   High-risk (HR) 47 (78)
EMR: Endoscopic mucosal resection; IQR: Interquartile range; X: 
Indefinite.
Table 2  Tumour index endoscopic mucosal resection 
characteristics n  (%)
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had LVI+ or LVIX and of these 9 patients, 4 patients 
were found to have LNM (44%); 16/22 patients had G3 
tumours and of these, 4 had LNM (25%). In total 8/22 
tumours were G3 and showed LVI+ or LVIX. Thus 4/8 
(50%) of these had LNM.
Three of the 4 patients found to have LNM on their 
surgical resection specimen received adjuvant CRT. Two 
patients have died of their disease and 2 patients were 
alive at last follow-up, 87 and 55 mo after their initial 
EMR.
Conservative treatment
A total of 38/60 (63%) patients were treated with con-
servative endoscopic follow-up. Twelve of these patients 
had LR disease and 26 had HR disease. It was concluded 
at the MDM that 11 of 12 patients with LR tumours 
had been cured of OAC and endoscopic follow-up was 
indicated. One patient underwent radiotherapy to reduce 
the risk of metachronous LNM. This patient was alive and 
disease-free at most recent follow-up.
The main indication for non-surgical treatment of 
patients with HR tumours (24 of 26 patients) was poor 
surgical fitness due to co-morbidities and high anaes-
thetic risk; 2 surgically fit patients chose a conservative 
approach after discussing the long-term risk for cancer 
recurrence and LNM. Of the 26 HR tumours, 7 patients 
had additional RFA and/or EMR of the remaining BE 
segment, 14 patients received adjuvant CRT, whilst five 
patients had regular endoscopic follow up alone.
In 6/38 (16%) patients treated conservatively, LNM 
were detected at 3, 4, 4, ,13, 17 and 38 mo after the 
EMR. These LNM were detected with PET CT and EUS 
and 4 of the 6 patients had LN sampling to confirm LNM. 
These were all HR lesions and represent 23% of HR 
tumours treated conservatively (Table 4). All 6 of these 
patients received CRT once the LNM were identified. 
1 of these 6 also underwent an EMR for a visible oeso-
phageal lesion. This latter patient remains alive after 
26-mo follow-up, whereas the 5 others have died of 
their disease. Of these 6 patients, all had an R1 EMR 
resection specimen; 5 of 6 patients had Sm2/3 tumours; 
3 of 6 patients either had LVI+ or were LVIX; and 2 of 6 
patients were G3.
LNM risk prediction
LNM were detected in 10 of 60 (17%) patients. With 
regard to treatment modality, LNM were detected in 
4/22 (18%) patients treated surgically and 6/38 (16%) 
treated conservatively. All patients with LNM had a HR 
OAC (10 of 47, 21%). None of the 13 patients with a LR 
lesion developed metastatic disease during follow-up. 
When stratified by risk factor, 1/25 (4%) of Sm1 cancers 
compared with 9/35 (26%) of Sm2/3/X lesions showed 
LNM (P = 0.035); 3/40 (8%) with no LVI compared with 
7/20 (35%) positive for LVI/X tumours showed LNM (P 
= 0.012); 4/30 (13%) of G1/2 tumours compared with 
6/30 (20%) of G3 tumours showed LNM (P = 0.488); 
and 0/17 (0%) of R0 tumours compared with 10/43 
(23%) for R1 tumours showed LNM (P = 0.049). An 
overview of all patients with LNM is provided in Table 4. 
Long term clinical outcomes and overall patient survival
At the end of the study 43 of 60 (73%) patients were 
alive with a median follow-up time of 45 mo (IQR 32-72; 
Case Endoscopic resection specimen Surgical resection specimen Note
 Sm, G3, LVI-, R Ta, LVI-, R0 /
2 Sm, G3, LVI-, R Tb Sm, G3, R0 /
3 SmX, G2, LVI-, R Tb, G3, LVI-, R0 /
4 Sm2/3, G3, LVI-, R No residual cancer LGD in surgical margin
5 Sm, G2, LVI-, R No residual cancer HGD in surgical margin
6 Sm, G3, LVI-, R Tb, G2, R0 /
7 Sm2/3, G3, LVI+, R Ta, G3, R0 Positive for LNM (2/6)
8 Sm2/3, G2, LVI-, R No residual cancer LGD in surgical margin
9 Sm2/3, G3, LVI-, R No residual cancer /
0 Sm2/3, G3, LVI-, R Ta, G3, LVI+, R0 /
 Sm2/3, G3, LVIX, R Tb, G2, R0 Positive for LNM (3/2)
2 Sm2/3, G3, LVI+, R T2, G3, R R, negative for LNM (6), preop EUS Tb
3 Sm2/3, G2, LVI+, R No residual cancer /
4 Sm, G3, LVI+, R Tb, G, LVI-, R0 /
5 SmX, G3, LVI+, R Tb, G3, R0 Positive for LNM (/23)
6 Sm2/3, G3, LVI+, R No residual cancer /
7 Sm, G3, LVIX, R T2, R0 Preop EUS T stage
8 SmX, G3, LVI+, R T3, G3, R0 Positive for LNM (3/78), preop EUS Tb
9 Sm2/3, G3, LVI-, R Ta, G3, R0 /
20 Sm2/3, G2, LVI-, R T, R0 /
2 SmX, G3, LVI-, R No residual cancer /
22 Sm, G2, LVI-, R0 No residual cancer LR tumour, HGD in surgical margin
Table 3  Histopathologic tumour characteristics of all patients with T1b oesophageal adenocarcinoma on endoscopic mucosal 
resection who underwent surgery - comparison of endoscopic and surgical resection specimens’ pathology report
Sm: Submucosal invasion < 500 μm; Sm2/3: Submucosal invasion > 500 μm; G: Well differentiated tumour; G2: Moderately differentiated tumour; 
G3: Poorly differentiated tumour; LVI: Lymphovascular invasion; R0: Complete resection; R1: Incomplete resection; X: Indefinite; LNM: Lymph node 
metastases; LGD: Low grade dysplasia; HGD: High grade dysplasia; LR: Low-risk tumour; HR: High-risk tumour.
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range 24-102). The median survival of the 17 of 60 (27%) 
deceased patients was 24 mo (IQR 9-40; range 3-59) 
from EMR diagnosis of pT1b OAC. Of these 17 deceased 
patients, 7 (42%) died of OAC and 10 (58%) died of 
non-OAC-related conditions: one patient died after a 
cerebrovascular accident, 2 patients died of renal cancer, 
and 7 patients died due to complications of ischaemic 
heart disease. 
Within the HR group 14 of 47 patients (30%) died 
during the follow-up period. Of these, 7 died of OAC. We 
found no significant difference for OAC-related deaths 
during the follow-up period when comparing treatment 
modality. 5/38 patients treated conservatively (13%) 
died of OAC whilst 2/22 patients (9%) of those treated 
surgically died of OAC (P = 0.636). Importantly, OAC-
related survival time remains comparable (P = 0.436) 
when one compares only the HR patients that underwent 
surgery (2/22) to the HR patients that received 
conservative management (5/26). The median overall 
survival of patients in the surgery group compared to 
patients in the conservative group was better, 45 mo 
(IQR 32-56; range 8-102) and 39 mo (IQR 24-50; range 
3-94), respectively (P = 0.019). However, after excluding 
patients who died of non-OAC-related causes (disease-
specific survival), the difference was no longer statistically 
significant (P = 0.376) (Figure 3). Patients in HR-surgery 
group similarly had a better overall survival compared to 
patients in HR-conservative group: median of 44 mo (IQR 
31-55, range 8-102) and 36 mo (IQR 23-50, range 3-94), 
respectively (P = 0.012). Again, after excluding patients 
who died of non-OAC-related causes, the difference was 
no longer statistically significant (P = 0.181) (Figure 4).
During the follow-up period 3/60 (5%) patients 
developed a local recurrence, 1 patient from the LR 
group and 2 patients from the HR group. The patient 
within the LR group had undergone an oesophagectomy 
as baseline therapy. The surgical resection specimen 
demonstrated residual HGD and the patient developed 
a T1a M3 tumour at the anastomosis after 47 mo. This 
was successfully resected by EMR and the patient has 














 Sm2/3, G3, LVIX, R Surgery 4 Chemotherapy Deceased OAC 45
2 SmX, G3, LVI+, R Surgery 2 None Alive / 87
3 SmX, G3, LVI+, R Surgery 4 CRT Deceased OAC 8
4 Sm2/3, G3, LVI+, R Surgery 2 Chemotherapy Alive / 55
5 Sm2/3, G3, LVIX, R Conservative 38 CRT Deceased OAC 40
6 Sm2/3, G2, LVI+, R Conservative 4 CRT Deceased OAC 9
7 Sm2/3, G2, LVI-, R Conservative 3 CRT Deceased OAC 3
8 Sm2/3, G2, LVI+, R Conservative 4 CRT Deceased OAC 8
9 Sm, G2, LVI-, R Conservative 7 EMR Ta, CRT Alive / 26
0 Sm2/3, G3, LVI-, R Conservative 3 Radiotherapy Deceased OAC 30
Table 4  Levels of sIL-2R, ALT, and HBV DNA in the sera of patients with chronic HBV infection (mean ± SD)
Time from index EMR until LNM/metastatic disease; 2Time from index EMR until the end of the study or death of the patient. EMR: Endoscopic mucosal 
resection; LNM: Lymph node metastases; Sm: Submucosal invasion < 500 μm; Sm2/3: Submucosal invasion > 500 μm; G2: Moderately differentiated 
tumour; G3: Poorly differentiated tumour; LVI: Lymphovascular invasion; R0: Complete resection; R: Incomplete resection; X: Indefinite; CRT: 





















log-rank test p  = 0.376
Figure 3  Kaplan-Meier disease-specific survival curve of all patients 
treated conservatively and surgically. There was no statistically significant 























log-rank test p  = 0.181
Figure 4  Kaplan-Meier disease-specific survival curve of patients with 
high-risk tumours treated conservatively and surgically (excluded were 7 
patients from high-risk-conservative group who died of non-oesophageal 
adenocarcinoma-related cause). There was no statistically significant 
difference, although a trend towards a better survival of surgery patients is 
observed. 
8 November 7, 208|Volume 24|Issue 4|WJG|www.wjgnet.com
survived to 50 mo at the end of the study. In the HR 
group, two patients with an R1 EMR specimen who 
were treated conservatively developed T1a and T1bSm1 
tumours at the site of previous resection after 6 and 
10 mo, respectively. Both tumours were successfully 
resected by EMR. One of these individuals was also found 
to have LNM and received CRT. Both of these patients 
were alive at last follow-up.
One of 12 patients within the LR-conservative group 
received CRT following MDT discussion. 9/12 patients 
remain alive with those who have died doing so from a 
cause unrelated to OAC (renal cancer, ischaemic heart 
disease and a cerebrovascular accident).  13 of 26 (50%) 
patients within the HR-conservative group received CRT. 
Of those who received CRT 7 have died although 5 (38%) 
of those were due to OAC. Of those who did not receive 
CRT 5 patients have died, although none of these deaths 
were due to OAC. 
DISCUSSION
This single centre retrospective analysis of 60 patients 
with T1b OAC suggests that patients with Sm1 tumours 
without high-risk histopathological markers can be 
treated endoscopically with good long-term outcomes. 
This is in keeping with other recently published studies. 
Within this LR group, none of the 13 patients had or 
developed LNM within the follow-up period. 12 patients 
were treated conservatively and the one patient who had 
surgical treatment was found to have a local recurrence, 
successfully endoscopically resected, 47 mon after the 
initial EMR. These data support the emerging treatment 
strategy that patients with LR T1b lesions should be 
offered EET and conservative treatment.
Of the patients with HR lesions that underwent sur-
gical resection, 4 (18%) were found to have LNM within 
their resection specimens. All 4 of these were G3 tumours 
with either LVI or were LVIX. Of those who had the 
combination of both of these high-risk histopathological 
features 50% (4/8) developed LNM suggesting that 
these patients are high-risk and EET carries higher risk 
of LNM and recurrence. None of the Sm1 tumours with 
only one high-risk histopathological feature had LNM. 
Although the numbers are too small to recommend chan-
ges to the existing treatment strategy, this data suggest 
that endoscopic resection and conservative management 
may be an appropriate approach for some patients cate-
gorised as high-risk where only one high-risk pathological 
feature is confirmed. This is highlighted by the fact 
that only 23% of HR tumours treated conservatively 
developed LNM during the follow-up period. Further pro-
spective RCT studies of surgical versus conservative treat-
ment strategies with higher patient numbers are required 
to explore this potential change in treatment paradigm.
Our data on LR and HR T1b cancers and clinical out-
comes are similar to the limited published series on this 
patient cohort. Manner et al[16] examined 72 patients with 
pT1bSm1 pathology on EMR specimens retrospectively 
over a 14 year period form their centre. These authors 
also differentiated LR and HR lesions based on criteria 
similar to our cohort. In the LR patients (n = 49) only 
one patient developed LNM (2%) at follow-up and in the 
HR group (n = 22) only two patients developed LNM 
(8.7%). In a similar study, Scholvinck et al[18] analysed 
69 patients with pT1b cancers, with their LR group 
having no LMN detected at follow-up, whereas the HR 
group displayed an overall LNM rate of 16% which is 
similar to our series. 
Clearly the decision-making in offering patients con-
servative treatment with EET or more radical therapy with 
surgery is complex and multifaceted with factors such 
as a patient’s fitness for surgery and patient preference 
influencing the final decision. The main advantage of 
surgery is that the entire organ and draining lymph 
nodes are cleared minimising LNM risk. However, even 
in high-volume expert centres, the 30-d mortality from 
oesophagectomy ranges between 2% and 5 %. There 
were no surgery-related deaths in our cohort, but the 
argument for approaching LR T1b OAC with endoscopic 
therapy is based on the published data where the rate on 
LNM is lower than that of surgical mortality. 
There was no statistically significant disease-specific 
survival benefit for patients treated surgically compared 
to patients treated conservatively in our study. Even in 
the high-risk patient group, although a trend toward 
better survival of surgery patients was observed, this was 
not statistically significant. Furthermore, OAC-related 
deaths were comparable in both groups. Here, we should 
highlight the high mortality of patients in our cohort due 
to conditions not related to OAC. There were 26% of 
patients in the conservative group who died of non-OAC-
related disease (none in the surgery group) and only 
13% died of OAC. It is important not to over-treat cancer 
in these patients. Furthermore, we observed that 2 out 
of 4 patients died of OAC despite oesophagectomy and 
removal of positive local lymph nodes. Thus, in these 
data, surgery did not always cure T1b OAC. One possible 
explanation is that the tumour had spread to lymph 
nodes outside the surgical resection field. Alternatively, 
a recently published study on metastatic colorectal 
cancer proposes a model that some distant metastases 
might arise independently of lymph node metastases[21]. 
If this were true for OAC, oesophagectomy with nodal 
clearance would not prevent metastatic disease due 
to haematogenous cancer spread. In this case (neo-
adjuvant) chemotherapy might be the preferred treat-
ment.
An unexpected feature in our cohort was a high 
percentage (84%) of incomplete (R1) endoscopic 
mucosal resections. This was at least partly due to our 
histopathologic criteria of at least 1 mm clear resection 
margin, which is difficult to achieve by EMR technique 
with tumours invading relatively thin oesophageal sub-
mucosal layer of approximately 1-1.5 mm. Thus, the 
percentage of R1 endoscopic resections in our cohort 
might have been overestimated. The evidence supporting 
this is that 32% of all patients in the surgery group 
(7/22) who were classified as R1 on EMR had no residual 
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cancer identified in the surgical resection specimen. In 
retrospect, even though none of these patients devel-
oped metastatic disease, surgery should not be con-
sidered over-treatment as all of these tumours, apart 
from 1, demonstrated other high-risk features. Possible 
overestimation of R1 endoscopic resections could also 
explain the relatively low rate of local recurrence and 
metastatic disease in patients with R1 EMR, who did not 
undergo additional resection (surgical or endoscopic). 
In conclusion, endoscopic therapy appears to be 
equal if not preferable to surgery in submucosal OAC 
with low-risk histopathologic features. In high-risk 
OAC, a conservative approach is a viable alternative to 
surgery, especially for selected patients and those with 
poor performance status. Further prospective studies 




This study provides long-term outcome data on patients with submucosal 
oesophageal adenocarcinoma.
Research motivation
The optimal management of submucosal oesophageal adenocarcinoma is not 
clearly defined. Data suggests endoscopic therapy may be a viable alternative 
to surgery and thus radically change the treatment paradigm. 
Research objectives
To analyse our data from a large tertiary specialist centre on the management 
of patients with submucosal oesophageal adenocarcinoma in order to support 
the potential for endoscopic therapy for these patients. In addition, we feel our 
work promotes the need for a large-scale multi-centre trial exploring endoscopic 
therapy for submucosal lesions.
Research methods
This was a retrospective cohort study that uniquely offers long-term outcomes 
on patients with high-risk and low-risk oesophageal submucosal lesions who 
received surgery and endoscopic therapy.
Research results
Lymph node metastases were detected in 18% of patients who had undergone 
conservative management. There was no statistically significant difference in 
tumour-related deaths between those treated surgically or conservatively and 
disease-specific survival time was also comparable between the two treatment 
strategies.
Research conclusions
This study provides supporting data for the potential of endoscopic therapy in 
the management of submucosal oesophageal adenocarcinoma. In particular, 
the work suggests that endoscopic therapy may be a viable alternative to 
surgery in selected patients. This work could support a change to the treatment 
strategy for submucosal lesions.
Research perspectives
Low-risk submucosal lesions can be safely treated endoscopically whilst our 
research suggests that endoscopic therapy may be a viable option for high-
risk lesions. This study supports the need for a large-scale multicentre study 
addressing this uncertainty in the treatment paradigm. 
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